(Las Vegas, Nevada, United States)  As per DelveInsight’s assessment, globally, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline constitutes 30+ key companies continuously working towards developing 30+ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. 

 

“EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market.

 

The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample pages here @ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline analysis

 

Some of the key takeaways from the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Report:

• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) companies across the globe are diligently working toward developing novel EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment therapies with a considerable amount of success over the years. 
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) companies working in the treatment market are Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others, are developing therapies for the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment 

• Emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapies in the different phases of clinical trials are ZD9291 80 mg/40 mg, Erlotinib 150/100mg, Dacomitinib, TAK-788, Pemetrexed, Cisplatin, Carboplatin, Dacomitinib (PF-00299804), Gefitinib, D-0316 Capsule, Icotinib Hydrochloride Tablets, Chemotherapy, and others are expected to have a significant impact on the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market in the coming years.
• In June 2023, ArriVent BioPharma, Inc. recently introduced a drug called furmonertinib, which is available in an oral form at a daily dose of 240 mg. This drug has progressed to the phase 2 stage and is currently being evaluated in a global, phase 3, randomized, multicenter, open-label study. The study aims to assess the effectiveness and safety of furmonertinib at two different dosage levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy. It specifically focuses on previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) who have Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations.
• AstraZeneca has introduced a drug called Osimertinib to the market in March 2023 following its successful completion of phase 2 clinical trials. The drug was evaluated in a multicenter, open-label, single-arm study that aimed to profile patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had a specific genetic mutation known as EGFR. Osimertinib was administered to these patients as part of the study to assess its effectiveness and safety in treating the disease.

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Overview

EGFR (epidermal growth factor receptor) mutation-positive non-small cell lung cancer (NSCLC) is a specific subtype of lung cancer characterized by genetic alterations in the EGFR gene. These mutations lead to uncontrolled cell growth and the development of tumors in the lungs. EGFR + NSCLC accounts for a significant portion of NSCLC cases, particularly in non-smokers or light smokers.

 

Patients with EGFR + NSCLC often present with distinct clinical features, such as younger age, Asian ethnicity, and a higher likelihood of having adenocarcinoma histology. EGFR-targeted therapies, including tyrosine kinase inhibitors (TKIs) like Osimertinib, have revolutionized the treatment of EGFR + NSCLC. These inhibitors specifically target the abnormal EGFR proteins, blocking their signaling pathways and effectively inhibiting tumor growth.

 

EGFR + NSCLC patients are typically stratified based on the presence of specific EGFR mutations, such as exon 19 deletions or the L858R point mutation, which can guide treatment decisions. EGFR TKIs have demonstrated superior efficacy and improved outcomes compared to traditional chemotherapy in EGFR + NSCLC patients. However, acquired resistance to EGFR-targeted therapies remains a challenge, leading to disease progression in the long term. Ongoing research efforts focus on developing combination therapies and novel agents to overcome resistance mechanisms and further improve patient outcomes in EGFR + NSCLC.

 

Get a Free Sample PDF Report to know more about EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

 

Emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Drugs under Different Phases of Clinical Development Include:

• DZD9008: Dizal Pharmaceuticals
• Nazartinib (EGF816) – Novartis Pharmaceuticals
• TY-9591: TYK Medicines
• CLN-081: Cullinan Oncology
• JIN-A02: J Ints Bio
• H002: RedCloud Bio
• BAY2927088: Bayer
• And Others.

 

EGFR Non-Small Cell Lung Cancer Route of Administration

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intramuscular
• Oral
• Intratumoral
• Intravenous
• Molecule Type

 

EGFR Non-Small Cell Lung Cancer Molecule Type

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules
• Product Type

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapeutics Assessment

• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Assessment by Product Type
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) By Stage and Product Type
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Assessment by Route of Administration
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) By Stage and Route of Administration
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Assessment by Molecule Type
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) by Stage and Molecule Type

 

DelveInsight’s EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) product details are provided in the report. Download the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline report to learn more about the emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapies at- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

 

Some of the key companies in the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Therapeutics Market include:

Key companies developing therapies for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) are Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Analysis:

The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment.
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs and therapies- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Market Drivers

The EGFR-positive non-small cell lung cancer (EGFR + NSCLC) pipeline market is driven by the development of targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs), which have shown superior efficacy compared to traditional chemotherapy, resulting in improved outcomes for patients.

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Market Barriers

One of the market barriers in the pipeline for EGFR mutation-positive non-small cell lung cancer (EGFR + NSCLC) is the emergence of acquired resistance to EGFR-targeted therapies, necessitating the development of innovative treatment strategies to overcome resistance and improve patient outcomes.

 

Scope of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Drug Insight    

• Coverage: Global
• Key EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Companies: Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others.
• Key EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Therapies: ZD9291 80 mg/40 mg, Erlotinib 150/100mg, Dacomitinib, TAK-788, Pemetrexed, Cisplatin, Carboplatin, Dacomitinib (PF-00299804), Gefitinib, D-0316 Capsule, Icotinib Hydrochloride Tablets, Chemotherapy, and others.
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Therapeutic Assessment: EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) current marketed and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) emerging therapies
• EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Dynamics: EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market drivers and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market barriers 

 

Request for Sample PDF Report for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

 

Table of Contents

1. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Report Introduction

2. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Executive Summary

3. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Overview

4. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Analytical Perspective In-depth Commercial Assessment

5. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapeutics

6. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Late Stage Products (Phase II/III)

7. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Mid Stage Products (Phase II)

8. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Early Stage Products (Phase I)

9. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Preclinical Stage Products

10. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Therapeutics Assessment

11. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies

14. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products

15. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Unmet Needs

16 . EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Drivers and Barriers

17. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Future Perspectives and Conclusion

18. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views

19. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting